Short Interest in ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Drops By 23.9%

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 80,400 shares, a drop of 23.9% from the February 29th total of 105,700 shares. Approximately 4.5% of the shares of the stock are short sold. Based on an average trading volume of 89,200 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of ThermoGenesis

Several institutional investors and hedge funds have recently modified their holdings of THMO. Virtu Financial LLC purchased a new stake in shares of ThermoGenesis in the 2nd quarter valued at about $52,000. Renaissance Technologies LLC grew its position in ThermoGenesis by 306.3% during the 3rd quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock worth $39,000 after acquiring an additional 117,600 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of ThermoGenesis in the 1st quarter worth approximately $40,000. Two Sigma Securities LLC bought a new stake in shares of ThermoGenesis in the 1st quarter worth approximately $37,000. Finally, Armistice Capital LLC bought a new stake in shares of ThermoGenesis in the 1st quarter worth approximately $328,000. Hedge funds and other institutional investors own 5.78% of the company’s stock.

ThermoGenesis Stock Up 1.5 %

NASDAQ:THMO opened at $0.71 on Friday. The business’s 50-day moving average price is $0.73 and its two-hundred day moving average price is $0.86. ThermoGenesis has a twelve month low of $0.36 and a twelve month high of $2.99.

About ThermoGenesis

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.